ERBB2 and breast cancer: Anti-HER-2001 × HBsAg, and anti-HER-2004 × HBsAg inflicted massive deaths of breast cancer cells, which were at statistically significantly much higher levels, than those inflicted by trastuzumab and anti-HER-2 biosimilars.